Eye care company Ocular Therapeutix ($OCUL) today announced the results of the Phase II trial of its Sustained Release Dexamethasone aimed at treating allergic conjunctivitis. The 42-day randomized, double-blind study of 68 patients showed that patients on the candidate had lower ocular itching and conjunctival redness scores than those on the placebo, the company said. The trial used a novel Conjunctival Allergen Challenge (CAC) Model due to the longer effect of the one-time administered sustained release drug product, according to a release. "A low-dose, sustained-release corticosteroid may alleviate the symptoms of allergic conjunctivitis without unwanted side effects," said CEO Amar Sawhney in a statement. "This Phase 2 trial provided valuable insight into the advantages of utilizing a modified CAC model, which we may incorporate into future trial design. We look forward to further clinical evaluation of the product for the treatment of allergic conjunctivitis." Release | ClinicalTrials.Gov